A literature review of influenza chemoprophylaxis and treatment in children
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This review examines recent studies on pediatric influenza prevention and treatment. Oseltamivir is a primary option, but optimal dosing and prophylaxis duration require further investigation for children.
Area Of Science
- Pediatrics
- Infectious Diseases
- Pharmacology
Background
- Influenza causes significant childhood hospitalizations and mortality.
- A therapeutic intervention gap exists for pediatric influenza.
- Recent literature is reviewed to address this gap.
Purpose Of The Study
- To review clinical trials and case reports on pediatric influenza prevention and treatment since 2019.
- To identify current therapeutic options and ongoing research areas.
- To assess the efficacy of existing and novel antiviral strategies.
Main Methods
- Literature search of PubMed and Cochrane Library for studies published since 2019.
- Inclusion of finished clinical trials and case reports in English.
- Focus on pediatric influenza prevention and treatment.
Main Results
- Oseltamivir, zanamivir, and baloxavir marboxil are recommended in Europe for influenza treatment/prophylaxis in children.
- Intravenous peramivir is approved by the FDA.
- Oseltamivir is the first-line treatment and chemoprophylaxis, with ongoing research into optimal dosage and prophylaxis duration.
Conclusions
- Oseltamivir remains a key agent for pediatric influenza, but optimal strategies are under evaluation.
- Continuous assessment of conventional and novel antivirals is crucial.
- Further research is needed to refine treatment protocols for children.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
• For...